1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis - Drugs In Development, 2022, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gingivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gingivitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.
Gingivitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gingivitis (Mouth And Dental Disorders).
- The pipeline guide reviews pipeline therapeutics for Gingivitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gingivitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gingivitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gingivitis (Mouth And Dental Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gingivitis (Mouth And Dental Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gingivitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gingivitis - Overview
- Gingivitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gingivitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gingivitis - Companies Involved in Therapeutics Development
- Amyndas Pharmaceuticals LLC
- Avicanna Inc
- Pacgen Life Science Corp
- Gingivitis - Drug Profiles
- AMY-101 - Drug Profile
- Product Description
- Mechanism Of Action
- BLXA-4ME - Drug Profile
- Product Description
- Mechanism Of Action
- KSL-W - Drug Profile
- Product Description
- Mechanism Of Action
- P-113 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize CB1 and CB2 for Gingivitis - Drug Profile
- Product Description
- Mechanism Of Action
- Gingivitis - Dormant Projects
- Gingivitis - Product Development Milestones
- Featured News & Press Releases
- Mar 09, 2021: Amyndas announces positive top-line phase 2 results for investigational AMY-101 in adults with periodontal inflammation and gingivitis
- Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
- Jan 24, 2017: Pacgen announces new markets for P113 products
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Gingivitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gingivitis - Pipeline by Amyndas Pharmaceuticals LLC, 2022
- Gingivitis - Pipeline by Avicanna Inc, 2022
- Gingivitis - Pipeline by Pacgen Life Science Corp, 2022
- Gingivitis - Dormant Projects, 2022
- Number of Products under Development for Gingivitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amyndas Pharmaceuticals LLC
- Avicanna Inc
- Pacgen Life Science Corp
